middle.news
Can Actinogen’s Xanamem Breakthrough Transform Alzheimer’s Treatment?
10:44am on Thursday 26th of February, 2026 AEDT
•
Biotechnology
Read Story
Can Actinogen’s Xanamem Breakthrough Transform Alzheimer’s Treatment?
10:44am on Thursday 26th of February, 2026 AEDT
Key Points
39% increase in net loss to $11.3 million for H1 FY26
Completion of enrolment in XanaMIA phase 2b/3 Alzheimer’s trial with 247 participants
Positive interim safety and efficacy recommendation from independent Data Monitoring Committee
FDA agreement on streamlined regulatory pathway including one further pivotal trial in 2027
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
ACTINOGEN MEDICAL (ASX:ACW)
OPEN ARTICLE